FA
TGTX icon

FCG Advisors’s TG Therapeutics TGTX Stock Holding History

FCG Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$409K Hold
15,300
– – 0.1% 112
2020
Q2 		$298K Hold
15,300
– – 0.08% 116
2020
Q1 		$151K Hold
15,300
– – 0.04% 150
2019
Q4 		$170K Buy
+15,300
New +$116K 0.05% 161

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FCG Advisors's TGTX Position: Q3 2020 in Review

FCG Advisors held its TG Therapeutics (TGTX) position steady in Q3 2020 at 15,300 shares worth $409K. The position accounts for 0.1% of the portfolio, ranked #112.

FCG Advisors first reported a position in TGTX in Q4 2019 and has held it in 4 quarters since. 181 funds tracked by Wall St. Rank hold TGTX as of Q3 2020.

  • FCG Advisors held 15,300 shares of TG Therapeutics worth $409K as of Q3 2020.
  • FCG Advisors left its TG Therapeutics share count unchanged in Q3 2020.
  • TG Therapeutics made up 0.1% of FCG Advisors's portfolio in Q3 2020, its #112 holding.
  • FCG Advisors first reported a position in TG Therapeutics in Q4 2019 and has held it in 4 quarters since.
  • 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2020.

Based on FCG Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.